A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

NCT01072149 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Fluticasone Furoate (FF)/GW642444 Inhalation Powder
DEVICE: placebo

Sponsor

GlaxoSmithKline